BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $1,224,101 | -64.9% | 106,629 | -61.5% | 0.06% | -68.8% |
Q3 2022 | $3,486,000 | -9.5% | 276,629 | -24.1% | 0.20% | -9.8% |
Q2 2022 | $3,854,000 | +25.4% | 364,252 | -11.7% | 0.22% | +100.0% |
Q4 2020 | $3,073,000 | +6.7% | 412,419 | -50.8% | 0.11% | -24.8% |
Q3 2020 | $2,881,000 | +38.5% | 838,719 | +92.1% | 0.15% | -25.5% |
Q2 2020 | $2,080,000 | -72.3% | 436,500 | -80.0% | 0.20% | -69.8% |
Q4 2019 | $7,521,000 | +873.0% | 2,179,950 | +2053.1% | 0.66% | +306.1% |
Q3 2018 | $773,000 | -1.7% | 101,245 | -32.5% | 0.16% | -29.1% |
Q3 2017 | $786,000 | +41.4% | 150,000 | +50.0% | 0.23% | +4.1% |
Q2 2017 | $556,000 | – | 100,000 | – | 0.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |